Paul Cooper - Concepedia

Author

Paul Cooper

Also Known As

B. Clarke, P Cooper, P N Cooper, P. Cooper, P. N. Cooper, P.N. Cooper, Paul Cooper, Paul N Cooper, Paul N. Cooper, S. Sorrentino

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

University of Liverpool Walton Centre University of Manchester University College London University Hospital of Wales

About

Paul Cooper is an author at University of Liverpool specializing in medicine, neurology, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	2.6K
2	Health Sciences	1	1	18
3	Public Health	1	1	26
4	Social Sciences	1	1	19
5	Biostatistics	1	1	26

Paul Cooper

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial Anthony G Marson, Asya M Al-Kharusi, Muna Alwaidh, The Lancet Partial EpilepsyPsychotropic MedicationPharmacotherapyNeurologyMedicine	2007	969
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial Anthony G Marson, Asya M Al-Kharusi, Muna Alwaidh, The Lancet Unclassifiable EpilepsyPsychiatryPsychotropic MedicationNeuromodulation TherapiesNeurology	2007	959
A governance model for the application of AI in health care Sandeep Reddy, Sonia Allan, Simon Coghlan, Journal of the American Medical Informatics Association	2019	765
Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause Amir Zaidi, Peter Clough, Paul Cooper, Journal of the American College of Cardiology Cardiovascular CauseNeurologyNeuroscienceNeuropathologyMedicine	2000	416
Ketogenic diet and other dietary treatments for epilepsy Cerian F Jackson, Robert G Levy, Paul Cooper Cochrane Database of Systematic Reviews	2016	242
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial Anthony G Marson, Girvan Burnside, Richard Appleton, The Lancet	2021	202
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial Anthony G Marson, Girvan Burnside, Richard Appleton, The Lancet	2021	183
Parkinson’s disease: summary of updated NICE guidance G Rogers, Debbie Davies, Joshua Pink, BMJ Motor DysfunctionNeurological DisorderClinical NeurologySymptomatic TreatmentNeurology	2017	111
C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease Matthew B. Harms, Bruno A. Benítez, Nigel J. Cairns, JAMA Neurology	2013	103
Sudden unexpected death in epilepsy genetics: Molecular diagnostics and prevention Alica M. Goldman, Elijah R. Behr, Christopher Semsarian, Epilepsia	2016	96

Page 1